Literature DB >> 30194558

Molecular pathways involved in microRNA-mediated regulation of multidrug resistance.

Rongrong Liao1, Yuexia Lin1, Lihui Zhu2.   

Abstract

Multidrug resistance (MDR) is still a major reason for therapeutic failure in cancers. The mechanisms underlying MDR are multifactorial and are not fully understood. miRNAs are evolutionarily conserved non-coding RNAs that function as key post-transcriptional regulators of gene expression. Emerging evidence indicates a vital role of miRNAs in the resistance to cancer treatments and suggests their potential for cancer therapy, as they can modulate multiple mechanisms link to the development of MDR. This review summarizes the recent findings on the role of miRNAs in MDR, and highlights the molecular targets and mechanisms of miRNA regulated pathways in MDR. Finally, the challenges and prospects of miRNA-targeted therapies for reversing drug resistance are reviewed.

Entities:  

Keywords:  Clinical trials; MiRNA; Pathway; Therapeutics

Mesh:

Substances:

Year:  2018        PMID: 30194558     DOI: 10.1007/s11033-018-4358-6

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  125 in total

1.  MiR-210 facilitates ECM degradation by suppressing autophagy via silencing of ATG7 in human degenerated NP cells.

Authors:  Cheng Wang; Zi-Zhen Zhang; Wei Yang; Zhi-Hua Ouyang; Jing-Bo Xue; Xue-Lin Li; Jian Zhang; Wen-Kang Chen; Yi-Guo Yan; Wen-Jun Wang
Journal:  Biomed Pharmacother       Date:  2017-06-28       Impact factor: 6.529

2.  Mir-30d suppresses cell proliferation of colon cancer cells by inhibiting cell autophagy and promoting cell apoptosis.

Authors:  Rui Zhang; Jian Xu; Jian Zhao; Jinghui Bai
Journal:  Tumour Biol       Date:  2017-06

3.  DNA damage responsive miR-33b-3p promoted lung cancer cells survival and cisplatin resistance by targeting p21WAF1/CIP1.

Authors:  Shun Xu; Haijiao Huang; Yu-Ning Chen; Yun-Ting Deng; Bing Zhang; Xing-Dong Xiong; Yuan Yuan; Yanmei Zhu; Haiyong Huang; Luoyijun Xie; Xinguang Liu
Journal:  Cell Cycle       Date:  2016-08-25       Impact factor: 4.534

4.  miRNA-34a is associated with docetaxel resistance in human breast cancer cells.

Authors:  L Kastl; I Brown; A C Schofield
Journal:  Breast Cancer Res Treat       Date:  2011-03-12       Impact factor: 4.872

Review 5.  Targeting multidrug resistance in cancer.

Authors:  Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

6.  Suppression of Dicer increases sensitivity to gefitinib in human lung cancer cells.

Authors:  Jui-Chieh Chen; Yen-Hao Su; Ching-Feng Chiu; Yi-Wen Chang; Yang-Hao Yu; Chi-Feng Tseng; Hsin-An Chen; Jen-Liang Su
Journal:  Ann Surg Oncol       Date:  2014-04-11       Impact factor: 5.344

7.  Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer.

Authors:  Michelle X Liu; Michelle K Y Siu; Stephanie S Liu; Judy W P Yam; Hextan Y S Ngan; David W Chan
Journal:  Oncotarget       Date:  2014-02-28

8.  miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer.

Authors:  Xiaohui Tan; Jin Peng; Yebo Fu; Shejuan An; Katayoon Rezaei; Sana Tabbara; Christine B Teal; Yan-gao Man; Rachel F Brem; Sidney W Fu
Journal:  Breast Cancer Res       Date:  2014-09-17       Impact factor: 6.466

Review 9.  Role of microRNAs in the resistance of prostate cancer to docetaxel and paclitaxel.

Authors:  Ewa Kopczyńska
Journal:  Contemp Oncol (Pozn)       Date:  2016-01-13

10.  miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway.

Authors:  Marijn T M van Jaarsveld; Patricia F van Kuijk; Antonius W M Boersma; Jozien Helleman; Wilfred F van IJcken; Ron H J Mathijssen; Joris Pothof; Els M J J Berns; Jaap Verweij; Erik A C Wiemer
Journal:  Mol Cancer       Date:  2015-11-17       Impact factor: 27.401

View more
  3 in total

1.  miR-26a Reverses Multidrug Resistance in Osteosarcoma by Targeting MCL1.

Authors:  Ming Li; Wei Ma
Journal:  Front Cell Dev Biol       Date:  2021-03-18

2.  LncRNA NNT-AS1 contributes to the cisplatin resistance of cervical cancer through NNT-AS1/miR-186/HMGB1 axis.

Authors:  Yanjie Liu; Ruixia Guo; Yuhuan Qiao; Liping Han; Mingzhu Liu
Journal:  Cancer Cell Int       Date:  2020-05-24       Impact factor: 5.722

Review 3.  Molecular Determinants of Cancer Therapy Resistance to HDAC Inhibitor-Induced Autophagy.

Authors:  Maria Mrakovcic; Leopold F Fröhlich
Journal:  Cancers (Basel)       Date:  2019-12-31       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.